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Inflammation contributes to the pathophysiology of
many diseases. In this report, we present noninva-
sive bioluminescence imaging methods that distin-
guish acute and chronic inflammation in mouse
models. Systemic delivery of luminol (5-amino-2,3-
dihydro-1,4-phthalazinedione) enables detection of
acute inflammation largely mediated by tissue-infil-
trating neutrophils, whose myeloperoxidase (MPO)
activity is required for luminol bioluminescence. In
contrast, bioluminescence from injection of lucigenin
(bis-N-methylacridinium nitrate) closely correlates
with late phase and chronic inflammation. Lucigenin
bioluminescence is independent of MPO and, in-
stead, requires phagocyte NADPH oxidase (Phox)
activity in macrophages. We are able to visualize
tissue inflammation resulting from wound healing,
bacterial infection, foreign substance implantation,
and antitumor immune responses. Given the central
role of inflammation in a variety of disorders, we
believe these noninvasive imaging methods can
help dissect the differential roles of neutrophils
and macrophages in a variety of pathological condi-
tions.
INTRODUCTION
As a fundamental aspect of human disease, inflammation is
a complicated biological response involved in wound healing
(Singer andClark, 1999),microbial infection (PremackandSchall,
1996), diabetes (Wellen and Hotamisligil, 2005), cancer (Weitz-
man and Gordon, 1990), cardiovascular (Ridker et al., 1997),
neurodegenerative (Wyss-Coray andMucke, 2002), and autoim-
mune diseases (Hamilton, 2008). Proper orchestration of inflam-
matory events is crucial not only for pathogen inactivation and
clearance by mediating innate and adaptive immunity, but it
also is important for tissue repair and disease resolution. Tissue
inflammation is largely mediated by neutrophils and mono-
cytes/macrophages. In the acute phase of inflammation, neutro-
phils are the first responders to tissue damage as a result of
bacterial infection, environmental exposure, and other harmful
stimuli (Harlan, 1985). The circulating neutrophils rapidly extrava-
sate from the blood vessels through interstitial tissues to the siteChemistry & Biology 19, 1199–120of injury (chemotaxis),where thecells inactivate invadingbacteria
by phagocytosis and releasing antimicrobial granules. Ingested
microbes fuse with granules to form phagosomes, within which
the cells produce high levels of intragranular superoxide (O2$
),
theprimary source ofmanydownstream reactive oxygen species
(ROS). The superoxide is then dismutated to hydrogen peroxide
(H2O2) by spontaneous dismutation, particularly at low pH within
phagosomes, or to a lesser extent by superoxide dismutase
(SOD) (Bedard and Krause, 2007; Rest and Spitznagel, 1977).
Hydrogen peroxide can be further converted to antimicrobial
hypochlorous acid (HOCl) in the presence of myeloperoxidase
(MPO) (Hampton et al., 1998). The activated neutrophils then
undergo programmed cell death (Serhan and Savill, 2005). As
the inflammatory reaction progresses, circulating monocytes
gradually move into the site of injury and differentiate into
mature macrophages (Singer and Clark, 1999). In addition to
direct phagocytosis of pathogens and cell debris, activated
macrophages can turn off inflammationbyproducing anti-inflam-
matory cytokines (Serhan and Savill, 2005). Macrophages pro-
mote tissue repair by production of extracellular ROS at a
lower level (Bedard and Krause, 2007). The ROS generated at
this later stage of inflammation play pleiotropic roles in tissue
remodeling, new vessel formation, and reepithelialization (Jiang
et al., 2011).
Both neutrophils andmacrophages rely on phagocyte NADPH
oxidase (Phox) as the primary source of superoxide production
(Bedard and Krause, 2007). Phox has multiple components
whose assembly is tightly regulated (Bedard and Krause, 2007).
It is comprised of a membrane-bound heterodimer cytochrome
b558 (consisting of subunits CYBA and CYBB), as the reaction
core, and several cytosolic regulatory subunits (p67phox,
p47phox, p40phox, and RAC). CYBB (also known as p91phox and
NOX2) is the key subunit that carries out the primary redox chain
reaction (Bedard and Krause, 2007). In resting neutrophils, cyto-
chrome b558 is mostly found in the membrane of intracellular
storage granules, and only a small fraction is present in the
plasma membrane (Calafat et al., 1993). Upon phagocytosis of
opsonized bacteria, cytochrome b558 and all necessary regula-
tory subunits are translocated to phagosomes, where they are
assembled into active holoenzymes (Bedard and Krause,
2007). Together with theMPOwithin phagosomes, the neutrophil
Phox exerts itsmicrobicidal power by rapid oxygen consumption
andROSproduction, aphenomenon termed the respiratory burst
(Hampton et al., 1998). In contrast,macrophage cytochromeb558
is mostly found in the plasmamembrane (Johansson et al., 1995)
and some is found in the intracellular compartments, which
serves as a recycling pool of the enzyme core (Ejlerskov et al.,9, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1199
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levels of MPO expression in intracellular vesicles (Kumar et al.,
2004). Thus, neutrophil Phox has a direct role in antimicrobial
activity, whereasmacrophages usePhox to generate superoxide
for regulatory functions (Johansson et al., 1995).
Because inflammation is a multistep in vivo process, molec-
ular imaging methods specific for different phases of inflam-
mation would allow noninvasive assessment in a longitudinal
manner. Prior studies have demonstrated the ability to image
MPO activity in vivo using luminol-based bioluminescence
(Gross et al., 2009; Kielland et al., 2009; Zhou et al., 2012) or
MRI methods (Chen et al., 2008). As MPO activity is predomi-
nantly present in neutrophils and monocytes in the acute
phases of inflammation, these methods were not suitable for
monitoring late phase or chronic inflammation, which is believed
to be more relevant to many human disorders. In this manu-
script, we demonstrate the use of a chemoluminescent agent,
lucigenin (bis-N-methylacridinium nitrate), for noninvasive
imaging of macrophages in association with late (chronic)
stages of inflammation. This pair of substrates allows visualiza-
tion of these cells in a noninvasive manner, thus allowing the
longitudinal assessment of inflammatory phagocyte populations
across both the acute and chronic phases of inflammation.
RESULTS
Bioluminescence Imaging of Tissue Inflammation with
Lucigenin and Luminol
Lucigenin has beenwidely used as a chemoluminescent agent to
detect superoxide anion (O2
) in vitro and ex vivo (Dikalov et al.,
2007). We tested its capability to image tissue inflammation in
immune compromised NCr nude mice with opportunistic Cory-
nebacterium bovis infection of the skin characterized by scaly
dermatitis and hyperkeratosis. After intraperitoneal (i.p.) injection
of 25mg/kg of lucigenin, bioluminescence was found to be local-
ized to areas of dermatitis (Figure 1A). In mice with ulcerative
dermatitis due to fighting, lucigenin bioluminescence was also
apparent in the wounds (Figure 1B).
Although these sporadic nonexperimental wounds suggest
specificity of lucigenin bioluminescence for areas of inflam-
mation, they yield little information about the state of inflamma-
tion (acute versus chronic) or the cellular mediators (neutrophils
versus macrophages). Using models with more defined inflam-
matory status and better reproducibility, we compared lucigenin
bioluminescence to luminol, a substrate capable of imagingMPO
activity associated with tissue-infiltrating neutrophils (Gross
et al., 2009). In a chronic inflammationmodel, we subcutaneously
(s.c.) implanted drug-releasing pellets onto nude mice (Fig-
ure 1C). The sites of pellet implantation were examined 4months
after implant, long after the depletion of the embedded agent
(b-estrabiol-17-acetate, 0.18 mg; 60 day controlled release).
Long-term exposure to synthetic material is known to trigger
macrophage infiltration to wall off the foreign material as a pro-
tectivemechanism (Salthouse, 1984). Notably, lucigenin imaging
(25 mg/kg i.p.) generated significantly higher levels of biolumi-
nescence compared with luminol imaging at a higher dose
(100 mg/kg i.p.; p = 0.0002).
In a separate study, we sterilely introduce surgical wounds
to the skin of nude mice (Figure 1D). Bioluminescence imaging1200 Chemistry & Biology 19, 1199–1209, September 21, 2012 ª201was performed after 4 days when surgical staples were
removed. Similar to pellet implants, we observed significantly
higher lucigenin signal compared with luminol (p < 0.0001).
These results suggest that lucigenin bioluminescence is more
specific for imaging late phase or chronic inflammation com-
pared to luminol.
We next used longitudinal imaging to assess bioluminescence
from lucigenin and luminol in a temporal manner. Local tissue
inflammation was induced by s.c. injection of 50 mg of phor-
bol 12-myristate 13-acetate (PMA), a potent protein kinase C
(PKC) agonist that activates phagocyte NADPH oxidase for
superoxide anion production and triggers intense acute inflam-
matory responses (Karlsson et al., 2000). The strong immune
responses cause rapid skin irritation and inflammation (Gross
et al., 2009). Daily imaging of both lucigenin and luminol biolumi-
nescence was performed for 4 days (Figure 1E). As early as 3 hr
after PMA injection, we observed significant luminol biolumines-
cence at the injection sites. On day 2, we observed scab
formation, which attenuated light penetration and thus reduced
luminescence intensity for both reagents. Starting on day 3, as
wound contraction and scab formation was visible (Figure 1E,
days 3 and 4), we observed steady increase of lucigenin biolumi-
nescence (Figure 1F). These results demonstrate that luminol
bioluminescence is associated with the acute phase of inflam-
mation, whereas lucigenin bioluminescence is preferentially
associated with the late phases of inflammation. These results
also suggest that luminescence from these different substrates
are mediated through distinct cell types and mechanisms.
Phagocyte MPO Activity Is Not Required for Lucigenin
Bioluminescence
Prior studies have established that in vivo luminol biolumi-
nescence depends upon MPO activity (Gross et al., 2009). To
investigate whether MPO is required for lucigenin biolumines-
cence, we s.c. injected 50 mg of lipopolysaccharide (LPS) in
the hind legs of wild-type (WT) and Mpo-knockout (Mpo/)
mice and performed longitudinal bioluminescence imaging for
up to 10 days (Figure 2A). LPSs are membrane components
and potent endotoxin of Gram-negative bacteria. LPS injection
mimics bacterial infection and triggers strong inflammatory re-
sponses in animals. Lucigenin bioluminescence did not depend
upon active MPO, because both WT and Mpo/ animals
showed identical steady increase in lucigenin signal (Figure 2B).
In contrast, MPO deficiency greatly affected luminol biolumines-
cence especially in the early phase of inflammation (Figure 2B,
lower panel, days 3–4).
In a separate study, we induced local tissue inflammation by
s.c. injection of PMA into WT and Mpo/ mice. At early stages
of inflammation (3 hr after PMA injection), luminol biolumines-
cence was significantly reduced in Mpo/ animals (Figures 2C
and 2D). In contrast, in the late stages of inflammation (3 days
after PMA inoculation), the lucigenin bioluminescence was not
affected by MPO deficiency (Figures 2C and 2D). These results
confirm that luminol bioluminescence is dependent upon MPO
activity, whereas lucigenin bioluminescence does not require
MPO. Together, the differences in enzyme requirements and
temporal peak in activity suggest that lucigenin bioluminescence
is not mediated by neutrophils, as is the case for luminol (Gross
et al., 2009).2 Elsevier Ltd All rights reserved
Figure 1. In Vivo Inflammatory Biolumi-
nescence Imaging Using Lucigenin and
Luminol
(A) Lucigenin bioluminescence in an NCr nude
mouse with sporadic C. bovis skin infection. In-
traperitoneal (i.p.) injection of lucigenin (25 mg/kg)
resulted in bioluminescence signal colocalized to
scaly dermatitis lesions.
(B) Lucigenin imaging of ulcerative dermatitis (fight
wound) in a nude mouse.
(C) Long-term pellet implant sites (red arrows)
preferably generate lucigenin bioluminescence
signal. Mice were imaged 4 months after pellet
implant with lucigenin (25 mg/kg i.p.) or luminol
(100 mg/kg i.p.; p = 0.0002, lower panel).
(D) Inflammatory bioluminescence in healing skin
lacerations. We performed lucigenin and luminol
imaging 4 days after introducing surgical skin
lacerations, when the lesions had started to heal.
(E) Longitudinal bioluminescence imaging of acute
and late phase inflammation. We induced local
tissue inflammation by s.c. injection of 50 mg PMA,
and performed daily lucigenin (25 mg/kg, i.p.) and
luminol (100 mg/kg, i.p.) bioluminescence imaging
starting at 3 hr after PMA injection.
(F) Quantitative representation of luminol and
lucigenin bioluminescence at injection sites. In the
acute phase of inflammation, luminol signal
dominated the bioluminescence output (3 hr, p <
0.0001). In the later stages of inflammation, the
sites of injection had higher lucigenin biolumines-
cence compared with luminol (day 4, p = 0.0201).
Data are represented as mean ± SEM.
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Phox
Wenext investigated whether Phox, the primary source of super-
oxide production in activated phagocytes, is required for in vivo
lucigenin bioluminescence. To selectively suppress Phox ac-
tivity, we took advantage of a selective inhibitor, apocynin (also
known as acetovanillone; molecular weight [MW] = 166.17),
which is a nontoxic natural organic compound structurally
related to vanillin. After activation by hydrogen peroxide in the
presence of peroxidase activity (such as MPO in phagocytes),
apocynin forms oligomers (di- or trimer) that prevent Phox
assembly on the membrane (Touyz, 2008). Once apocynin is
removed from the cells, the enzyme complex gradually restoresChemistry & Biology 19, 1199–1209, September 21, 2012 ªits function. We first tested apocynin in
the pellet-implanted mice with prominent
lucigenin bioluminescence (Figure 1C).
After baseline imaging (t = 0), animals
were treated with two doses of apocynin
within 24 hr. Posttreatment imaging re-
vealed significant reduction in lucigenin
bioluminescence (Figure 3A), with grad-
ual recovery to original levels within
3 days after treatments (Figure 3B). In
PMA-injected animals, we also tested
whether apocynin suppresses luminol
bioluminescence at early stages of
inflammation (5 hr after injection, Fig-ure 3C), and lucigenin bioluminescence at later inflammatory
stages (4 days after injection, Figure 3D). Both luminol and luci-
genin imaging showed significant reduction in bioluminescence
mediated by apocynin treatments (p = 0.0012 and p = 0.0093,
respectively).
Apocynin is not entirely specific because its oxidized oligo-
mers may affect targets other than Phox in phagocytes. Further-
more, in the absence ofMPO, apocynin can act as an antioxidant
(Touyz, 2008). To verify that Phox is the only NADPH oxidase
responsible for inflammatory bioluminescence, we performed
imaging in Cybb-knockout (Cybb/) mice compared to WT
controls. CYBB is a highly glycosylated transmembrane subunit
of Phox, which carries out the primary redox chain reaction from2012 Elsevier Ltd All rights reserved 1201
Figure 2. Phagocyte MPO Activity Is Not Required for Lucigenin Bioluminescence
(A) LPS (50 mg) was injected s.c. into the hind legs of wild-type (WT) andMpo-knockout mice (Mpo/). Longitudinal bioluminescence imaging with lucigenin and
luminol was performed daily for 10 days.
(B) Quantitative representation of luminol and lucigenin bioluminescence at LPS injection sites.
(C) Local tissue inflammation was induced by s.c. injection of PMAontoWT andMpo/mice.Wemonitored acute phase luminol signals (3 hr after PMA injection)
and late stage lucigenin bioluminescence (3 days after PMA injection).
(D) Quantitative representation of bioluminescence revealed differences in acute phase luminol signal (p = 0.0093), but no significant difference in late phase
lucigenin signal (p = 0.47).
Data are represented as mean ± SEM.
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oxygen, on the outside of the membrane (Bedard and Krause,
2007). In a late stage inflammatory model, we surgically intro-
duced skin wounds in bothWT andCybb/mice and performed
lucigenin and luminol imaging 4 days later (Figure 3E). We
observed dramatic reduction of both lucigenin and luminol biolu-
minescence in Cybb/ animals. These results indicate that
Phox is necessary for both lucigenin and luminol biolumines-
cence in these experimental inflammation models.1202 Chemistry & Biology 19, 1199–1209, September 21, 2012 ª201Macrophage Phox Is Responsible for Lucigenin
Bioluminescence
Because CYBB is highly expressed in all phagocytic cells
(Bedard and Krause, 2007), we next sought to determine the
specific cell type responsible for lucigenin inflammatory biolumi-
nescence. Compared with normal skin (Figure 4A), hematoxylin
and eosin (H&E) staining of the long-term s.c. pellet implant sites
showed massive macrophage infiltration and granuloma forma-
tion (Figure 4B) (Salthouse, 1984). Very few neutrophils were2 Elsevier Ltd All rights reserved
Figure 3. Both Luminol and Lucigenin
Require Phox to Generate Bioluminescence
(A) Apocynin, a reversible Phox inhibitor, sup-
pressed lucigenin bioluminescence in pellet-im-
planted animals. At hr = 0, baseline lucigenin
signal was established prior to i.p. apocynin
treatments at 0.5 hr and 22 hr. Lucigenin signal
was reassessed at 24, 48, and 96 hr.
(B) Quantitative representation of lucigenin biolu-
minescence in pellet-implanted animals. Apocynin
significantly suppressed lucigenin biolumines-
cence (hr = 0 versus hr = 24, p = 0.015), which, in
turn, gradually recovered to original levels. Dash
lines indicate apocynin treatments.
(C) Apocynin (APO) suppressed luminol biolumi-
nescence in early stages of inflammation. PMA
was s.c. injected at hr = 0 hr to induce tissue
inflammation. Animals received two apocynin
treatments (at 0 hr and 3 hr) prior to luminol lumi-
nescence imaging at 5 hr.
(D) APO suppressed lucigenin bioluminescence in
late stages of tissue inflammation (4 days after
PMA injection). Animals received apocynin treat-
ments 2 hr prior to bioluminescence imaging.
(E) Inflammatory bioluminescence imaging in
Cybb/ mice. CYBB is the catalytic subunit of
Phox. Surgical skin wounds were inflicted in both
WT and Cybb/ mice. Lucigenin and luminol
bioluminescence imaging was performed after
4 days.
(F) A significant reduction of both lucigenin (p =
0.0044) and luminol signals (p = 0.037) was
observed inCybb/ animals, indicating that Phox
is responsible for both inflammatory biolumines-
cence signals.
Data are represented as mean ± SEM.
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In Vivo Imaging of Inflammationobserved at the pellet implant sites. Because lucigenin domi-
nated the inflammatory bioluminescence in pellet implants (Fig-
ure 1C), this histopathological result suggests that macrophage
are responsible for lucigenin-mediated bioluminescence.
We investigated the histological differences between the
acute and late phases of inflammation in the PMA-stimulated
skin inflammation model. Within 12 hr after s.c. PMA injection,
we observed massive neutrophil infiltration at the site of injection
(Figure 4C), consistent with higher luminol bioluminescence we
previously observed (Figures 1E and 1F). Interestingly, after
4 days in the later stage of inflammation, we observed consider-
able infiltration of macrophages in the s.c. muscle layer beneath
the scab and granulation tissue (Figure 4C). This result is concor-Chemistry & Biology 19, 1199–1209, September 21, 2012 ªdant with higher lucigenin biolumines-
cence in our imaging studies (Figures 1E
and 1F).
To further elucidate the cell type
responsible for lucigenin biolumines-
cence, we assessed ex vivo biolumines-
cence using purified cell populations.
Resting splenocytes harvested from WT
mice demonstrated very low lucigenin
or luminol bioluminescence (Figure 4D).
Upon stimulation with PMA, which acti-
vates PKC signaling and Phox assembly(Jiang et al., 2011), we observed a significant increase in signal
output of both lucigenin and luminol bioluminescence. We
also tested whether the observed luminescence was caused
by peroxynitrite (ONOO), which can react with luminol or luci-
genin to produce light (Kahraman and Demiryu¨rek, 1997; Radi
et al., 1993). Between the two reagents, luminol is more reactive
and does not require MPO to generate light in this manner (Kah-
raman and Demiryu¨rek, 1997; Radi et al., 1993). Peroxynitrite is
highly reactive and is produced by superoxide anion (O2$
, from
NADPH oxidase) reacting with nitric oxide (NO$, from nitric
oxide synthase). However, the nitric oxide synthase inhibitor
L-NMMA failed to suppress either luminol or lucigenin lumi-
nescence after PMA-stimulation, suggesting that peroxynitrite2012 Elsevier Ltd All rights reserved 1203
Figure 4. Macrophage Phox Is Responsible for Lucigenin Bioluminescence
(A) Hematoxylin and eosin (H&E) staining of normal skin. Bar = 50 mm.
(B) H&E staining of the s.c. pellet implant sites revealed massive tissue-infiltrating macrophages and granuloma formation (arrows), with very few neutrophils.
(C) Twelve hours after s.c. PMA injection, massive neutrophil infiltration (arrowheads) was apparent at the site of injection. Four days after PMA injection, infil-
tration of macrophages (arrows) was apparent in the s.c. muscle layer beneath scab and granulation tissue.
(D) PMA stimulated luminol and lucigenin ex vivo bioluminescence in splenocytes. Naive splenocytes harvested from WT C57BL/6 mice (Ctrl) had very low
lucigenin and luminol bioluminescence, compared to PMA-stimulated cells.
(E) The nitric oxide synthase inhibitor L-NMMA (1 mM) failed to suppress either luminol or lucigenin luminescence in splenocytes after PMA stimulation.
(F) Lucigenin and luminol bioluminescence of magnetically purified neutrophils (Ly-6G+) and monocytes/macrophages (CD11b+).
Data are represented as mean ± SEM.
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(Figure 4E).
We next determined the bioluminescence of lucigenin and lu-
minol in magnetically purified Ly-6G+ neutrophils and in CD11b+
macrophages andmonocytes (Figure 4F). After PMA stimulation,
CD11b+ cells showed higher lucigenin bioluminescence than did
Ly-6G+ cells, indicating that macrophages or monocytes prefer-
entially activate lucigenin. On the other hand, luminol biolumi-
nescence was identical comparing Ly-6G+ and CD11b+ cells
(Figure 4F), suggesting that there isMPO expression in both puri-1204 Chemistry & Biology 19, 1199–1209, September 21, 2012 ª201fied cell types. In addition to neutrophils, monocytes have high
levels of MPO in intracellular vesicles where membrane-bound
Phox is also found (Calafat et al., 1993). However, circulating
monocytes lose MPO activity as they infiltrate and differentiate
into macrophages in tissue (Kumar et al., 2004).
In Vivo Imaging of Antitumor Immune Response and
Cancer Cell Eradication
To test whether inflammatory bioluminescence imaging could be
used to visualize immune responses, we used a nude mouse2 Elsevier Ltd All rights reserved
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adoptive transfer of antitumor splenocytes. To induce antixeno-
graft immunity, naive splenocytes from immune-competent WT
BALB/c donors were intravenously (i.v.) injected in syngenic
BALB/c nude mice bearing s.c. human HCT116 tumors. Within
2 weeks, when efficient tumor killing and necrosis was evident,
we harvested anti-HCT116 splenocytes and transferred cells
into a second cohort of HCT116 tumor-bearing nude mice to
further boost and enrich their anti-HCT116 immune memory.
Imaging of the second cohort of tumor-bearing mice revealed
inflammatory lucigenin and luminol bioluminescence 6 days
after splenocyte transfer (Figure 5A). Without splenocyte trans-
fer, control tumor-bearing animals showed no significant biolu-
minescence. After tumor necrosis was apparent, we harvested
the anti-HCT116 splenocytes from the second cohort and
transferred them into a third cohort of tumor-free BALB/c nude
mice. Control BALB/c nude mice received no immune-condi-
tioned splenocytes. After 8 weeks, when the antitumor immune
memory was established, we challenged both recipient and
control animals with s.c. inoculations of HCT116-Luc cells.
Luminescence imaging was performed 8 days after tumor
inoculation. Mice receiving conditioned splenocytes demon-
strated both lucigenin and luminol signals (Figure 5B), indicating
that macrophage and neutrophil activity was present at sites of
tumor eradication. Control mice exhibited low inflammatory bio-
luminescence. To verify antitumor immune responses, we mea-
sured the firefly luciferase activity associated with HCT116-
Luc tumor growth by i.p. injection of the substrate d-luciferin
(Figure 5C), demonstrating a significant antitumor effect.
DISCUSSION
In this study, we demonstrate that two luminescent substrates,
luminol and lucigenin, can be used to image different phases
of inflammation using noninvasive bioluminescence imaging.
Although luminol bioluminescence is mediated by neutrophils
in the acute phase, lucigenin bioluminescence is associated
with macrophages in the chronic phase of inflammation. Luminol
is a small unchargedmolecule (MW = 177.16, Figure 6A) that can
easily penetrate both plasmamembrane andmembrane of intra-
cellular vesicles such as phagosomes (Aitken et al., 1992; Allen
and Loose, 1976; Caldefie-Che´zet et al., 2002; Dahlgren et al.,
1985; Dahlgren and Karlsson, 1999). In addition to Phox, luminol
bioluminescence also relies on MPO to catalyze the light-emit-
ting reaction (Bedard and Krause, 2007). On the other hand,
lucigenin is a larger molecule (MW = 510.5, dinitrate salt, Fig-
ure 6B) with two positive charges, making it largely membrane
impermeable (Aerts et al., 1986; Aitken et al., 1992; Caldefie-
Che´zet et al., 2002; Dahlgren et al., 1985; Dahlgren and Karlsson,
1999). Taken together, our results suggest that the subcellular
location of the Phox holoenzyme assembly determines the cell
type specificity for the two substrates (Figure 6C). Although
both reagents depend upon Phox to provide superoxide anion
(O2$
), the disparity in cell permeability and MPO-dependency
establishes their utility for imaging different cell types and stages
of inflammation.
Phagocyte activation causes Phox assembly by recruiting
cytosolic regulatory components (p67/p40/p47 and the G
protein RAC, Figure 6C) to the membrane-bound cytochromeChemistry & Biology 19, 1199–120b558 reaction core (Bedard and Krause, 2007). In neutrophils
(or monocytes), most of the Phox is present in the membrane
of intracellular vesicles (phagosomes) (Calafat et al., 1993),
where high levels of MPO is also found. As a result, luminol
bioluminescence is preferentially localized within phagosomes
of activated neutrophils (or monocyte, to a lesser extent)
during acute inflammation. On the other hand, after maturation
from circulating monocytes, macrophages in tissue have lost
most of their MPO activity (Kumar et al., 2004) and, thus, do
not actively produce luminol bioluminescence. Macrophages
assemble Phox in the plasma membrane after activation
(Johansson et al., 1995), where nonpermeable lucigenin can
directly interact and produce inflammatory bioluminescence
extracellularly.
Lucigenin chemoluminescence reaction involves single-elec-
tron reduction of lucigenin (LC2+) to form lucigenin cation radical
(LC$+), which, in turn, reacts with superoxide anion (O2$
) to
produce light (Va´squez-Vivar et al., 1997). Superoxide alone
is unable to reduce lucigenin. An additional reducing agent,
such as NADH or NADPH, is required for measuring superoxide
anion level in tissue homogenate (Janiszewski et al., 2002).
In phagocytes, plasma membrane-bound Phox can achieve
single-electron reduction of extracellular lucigenin using intracel-
lular NADPH as the electron donor (Va´squez-Vivar et al., 1997).
There is concern about possible redox-cycling of lucigenin
cation radical (LC$+) that produces artificial superoxide anion
(O2$
) by reducing oxygen (O2) (Kielland et al., 2009; Tarpey
et al., 1999). However, lower oxygen pressure in tissue (10 mm
Hg, compared with 150 mm Hg in the atmosphere) and higher
affinity to endogenous superoxide anion (O2$
, with a nega-
tive charge opposite to LC$+), make it unlikely to occur in
phagocytes during in vivo imaging (Afanas’ev et al., 1999; Li
et al., 1998). The fact that Phox generates both lucigenin cation
radical (LC$+) and superoxide anion (O2$
) in the vicinity of
extracellular space makes lucigenin a selective reagent for
macrophage imaging.
Inflammation is an intricate multistep process that requires
proper orchestration of many cell types and various signaling
pathways. A simple and robust imaging method for inflamma-
tory imaging would greatly benefit biomedical research in
many disease areas. In this manuscript, we present the syner-
gistic use of both luminol and lucigenin to monitor acute and
late (chronic) phase inflammation in living animals. Because
these substrates are commercially available and relatively inex-
pensive, we believe this method can be readily translated to
many in vivo applications. Although their blue emission spectra
are not ideal for in vivo imaging, we are able to detect inflamma-
tory bioluminescence close to the body surface in our studies,
and we believe that this dual-agent (luminol/lucigenin) imaging
method is a good in vivo research tool with applications in
wound healing, infectious disease, and cancer biology. Further
modification of their chemical structures could potentially
generate luminol and lucigenin variants with better quantum effi-
ciency for stronger light output, or red-shifted emission spectra
for deeper tissue penetration. For example, L-012, a luminol
analog, has higher luminescence output in vitro (Imada et al.,
1999). It may be feasible to use L-012 instead of luminol for
more sensitive acute phase imaging in vivo (Kielland et al.,
2009; Zhou et al., 2012).9, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1205
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Figure 6. Different Mechanisms of Luminol
and Lucigenin Bioluminescence in Phago-
cytes
(A and B) Molecular structure of luminol (A) and
lucigenin (B).
(C) Schematic representation of cell-specific
imaging with luminol and lucigenin.
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Inflammation is a complicated biological process in re-
sponse to harmful stimuli, which can be divided into two
stages. During early (acute) stages of inflammation, the first
responders to tissue injury are predominantly neutrophils, in
which myeloperoxidase (MPO) activity is important for bac-
tericidal functions. Later stages of inflammation (chronic)
are characterized by monocyte/macrophage infiltration,
whose regulatory function is important for the healing pro-
cess and disease resolution. Previous studies have estab-
lished noninvasive imaging methods for monitoring neutro-
phil MPO activity during acute inflammation. However,
there is no imagingmethodcurrently available formonitoring
late stage and chronic inflammation in living animals.
Wedescribeabioluminescence imagingmethod for nonin-
vasively visualizing inflammation in living animals. Systemic
injection of luminol allows areas of acute inflammation to
be imaged, whereas injection of lucigenin visualizes areas
of chronic inflammation. Using mechanistic studies, we
have determined that, although acute phase luminol biolumi-
nescence is specifically mediated by the MPO activity in
neutrophils, in contrast, chronic phase lucigenin biolumines-Figure 5. In Vivo Imaging of Antitumor Immune Response and Cancer Cell Eradication
Antitumor immunity was established by adaptive i.v. transfer of immune-conditioned splenocytes (SPN), from
colorectal tumors. In the first round, naive SPNs harvested from immune-competent WT BALB/c mice were i.
nude BALB/c mice bearing s.c. HCT116 tumors. After two weeks of incubation, with clear signs of tumor regre
of tumor-bearing recipients to boost their anti-HCT116 immunity and memory.
(A) Bioluminescence imaging of the second cohort after 6 days of SPN transfer revealed significant lucigenin a
the antitumor immune responses. Control tumor-bearing animals (Ctrl) received no SPN transfer. Red arrow
(B) Immune-conditioned SPNs were harvested from the second-round animals a week later and were transfe
mice. Control animals (Ctrl) received no SPN transfer. After 8 weeks, both SPN recipient and control animals
cancer cells (indicated by red arrows). Lucigenin and luminol bioluminescence imaging of the third cohort w
(C) Tumor cell burden was assessed 12 days after inoculation of HCT116-Luc cells.
Data are represented as mean ± SEM.
Chemistry & Biology 19, 1199–1209, September 21, 2012 ªcence relies on the Phox activity in
macrophages. Together, these two
substrates allow for the longitudinal
noninvasive imaging of the inflamma-
tory cascade in experimental disease
models. Importantly, this imaging
method takes advantage of the endog-
enous enzymatic activities in phago-
cytes, and there is no need for ectopic
expression of reporters.
EXPERIMENTAL PROCEDURES
Animals, Cell Lines, and Reagents
We performed all animal studies under protocols
approved by the DFCI ACUC. BALB/c (BALB/cAnNCrl), BALB/c nude (CAnN.Cg-Foxn1nu/Crl), and NCr nude (Crl:NU[NCr]-
Foxn1nu) mice were purchased from the Charles River Laboratories (Wilming-
ton, MA). C57BL/6J,Mpo/ (B6.129X1-Mpotm1Lus/J) and Cybb/ (B6.129S-
Cybbtm1Din/J) mice were obtained from the Jackson Laboratory (Bar Harbor,
ME). HCT116 human colorectal cancer cells were engineered to express the
firefly luciferase by lentiviral transduction with FUW-Luc-mCherry-puro to
generate HCT116-Luc cells (Kimbrel et al., 2009). Luminol (5-amino-2,3-dihy-
dro-1,4-phthalazinedione), lucigenin (bis-N-methylacridinium nitrate), PMA
(phorbol 12-myristate 13-acetate), LPS (lipopolysaccharides from Salmonella
enterica serotype enteritidis), apocynin (40-hydroxy-30-methoxyacetophe-
none), and L-NMMA (NG-methyl-L-arginine acetate salt) were purchased
from Sigma-Aldrich Co. (St. Louis, MO). D-luciferin (potassium salt) was ob-
tained from Promega Co. (Madison, WI).
In Vivo Luminol and Lucigenin Bioluminescence Imaging
Lucigenin (2.5 mg/ml) and luminol (10 mg/ml) stock solutions were prepared in
normal saline prior to injection. We i.p. injected 10 ml/kg of stock solution into
animals to achieve final dosage of 25 mg/kg lucigenin or 100 mg/kg luminol.
After injection, animals were imaged using the IVIS Spectrum imaging system
(Caliper Life Sciences, Hopkinton MA) under compressed air containing
1%–2% of isoflurane. Serial bioluminescence images were acquired for
1 min with F/stop = 1 and binning = 16. Planar bioluminescence images
were presented as radiance in photon/sec/cm2/sr with minimal and maximal
thresholds indicated. We used the Living Image software package (version
4.2, Caliper Life Sciences) to calculate peak total tumor bioluminescent signal
through standardized regions of interest (ROIs). Data were presented as totaldonors previously exposed to HCT116-Luc human
v. transferred into syngenic immune-compromised
ssion, SPNs were transferred into a second cohort
nd luminol bioluminescence signal associated with
s indicate tumor locations.
rred into a third cohort of tumor-free BALB/c nude
were challenged with s.c. inoculation HCT116-Luc
ere performed 8 days after tumor challenge.
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In Vivo Imaging of Inflammationflux in photons per second per ROI. Tomonitor HCT116-Luc tumor growth, we
i.p. injected d-luciferin at 75 mg/kg (10 ml/kg of 7.5 mg/ml) and performed
serial acquisitions (0.5 s with F/stop = 1 and binning = 16) to determine peak
bioluminescence.
Animal Inflammation Models
To establish long-term inflammation, we s.c. implanted estrogen-releasing
pellets (b-estrabiol-17-acetate, 0.18 mg, 60 day control release, Innovative
Research of America, Sarasota, FL) onto NCr nude mice. Bioluminescent
imaging was performed 4 months later, when the residual effects of estrogen
wereminimal. A pellet and its surrounding skin tissue were harvested and fixed
in 10% formalin for conventional H&E staining. Tissue slides were viewed
under 43 or 103 object lens of an Olympus BH-2 upright microscope
(Olympus America, Center Valley, PA). To induce surgical lacerations, hair
on the flankwas removed using Nair and a small cut (10mm) wasmade using
a sterile scissor. A surgical staple (9 mm) was placed on each skin cut, which
was then removed 4 days later, prior to bioluminescent imaging. To induce skin
irritation and inflammation, we s.c. injected 50 mg of PMA in the flanks in 50 ml of
PBS containing 20% DMSO. Skin samples were harvested from mice and
fixed in 10% formalin 12 hr and 4 days after PMA injection. For s.c. PMA injec-
tion inWTC57BL/6 andMpo/mice, hair was removed with Nair prior to PMA
injection. Inflammatory bioluminescence was followed as early as 3 hr after
injection. For LPS injections, we s.c. injected 50 mg of LPS in 50 ml of PBS
onto the left hind legs of WT (C57BL/6) or Mpo/ mice, and followed their
inflammatory bioluminescence daily. Temporary inhibition of Phox activity
was achieved by apocynin treatment. For pellet-implant nude mice, the apoc-
ynin treatments were given by oral gavage at 10 mg/kg in water containing 5%
ethanol. For s.c. PMA-injected mice, the apocynin treatments were given by
i.p. injection at 15 mg/kg in normal saline containing 5% ethanol.
Antitumor Immune Response Model
To induce acquired antixenograft immunity, we transplantedWT BALB/c sple-
nocytes (1.5 3 107 cells per animal) into syngenic BALB/c nude mice bearing
s.c. HCT116-Luc tumors. Signs of tumor killing and eradication were visible
within 2 weeks. Splenocytes were then harvested and i.v. injected (4.0 3 107
per animal) into a second round of tumor-bearing BALB/c nude recipients to
boost their anti-HCT116 immunity and memory. Inflammatory imaging was
performed 6 days after splenocyte transfer. A week later, we harvested
immune-conditioned splenocytes from the second-round animals and trans-
ferred 4.0 3 107 cells into each tumor-free BALB/c nude mouse. Control
animals received no splenocyte transfer. After 8 weeks, we challenged the
animals by s.c. inoculation of 3 3 106 HCT116-Luc cells. Inflammatory biolu-
minescence imaging was performed 8 days after tumor challenge. To verify
tumor viability, we performed firefly luciferase bioluminescence imaging
12 days after tumor inoculation.
Ex Vivo Bioluminescence Imaging of Isolated Splenocytes
Spleenswere harvest fromeuthanizedmice prior to dissociation using amouse
spleen dissociation kit (Miltenyi Biotech, Auburn, CA) following the manufac-
turer’s instruction. Spleens were placed into gentleMACS C tubes (Miltenyi
Biotech) containing 5 ml of digestion enzyme cocktails. The tubes were
mounted onto gentleMACS dissociator (Miltenyi Biotech), which extracted
total splenocytes using a preprogrammed mouse spleen setting. We per-
formed a brief centrifugation to remove digestive enzyme cocktail and then
applied the cell suspension onto 70 mm strainers to remove tissue debris. Cells
were then washed once with the dissociation buffer from the kit. After centri-
fugation, harvested splenocytes were resuspended into PEB buffer that
contained 0.5% of bovine serum albumin and 2 mM of EDTA in PBS. We per-
formed magnetic enrichment of granulocytes or monocytes/macrophages
using the MACS separation microbeads (Miltenyi Biotech) according to the
manufacturer’s instruction. For granulocyte isolation, splenocyte suspensions
were incubated with anti-Ly-6G-biotin antibody, followed bymagnetic labeling
using streptavidin-conjugated microbeads. For monocyte/macrophage isola-
tion, splenocyte suspensions were directly labeled with anti-CD11b microbe-
ads. Magnetically labeled granulocytes (Ly-6G+) and monocyte/macrophage
(CD11b+) were then isolated on a MACS separator. To image inflammatory
bioluminescence, unenriched splenocytes were loaded into wells on a black
96 well plate (2.5 3 107 cells/well, in 300 ml of PEB buffer containing 50 mM1208 Chemistry & Biology 19, 1199–1209, September 21, 2012 ª201of PMA). In each well, we added 20 ml of lucigenin (2.5 mg/ml) or luminol
(10 mg/ml) stock solution prior to IVIS acquisition for 5 min with F/stop = 1
and binning = 16. Inhibition of nitric oxide synthase is achieved by adding
L-NMMA to a final concentration of 1 mM in the reaction. For magnetically iso-
lated Ly-6G+ or CD11b+ splenocytes, similar bioluminescent assays were per-
formed with 1.5 3 106 cells in each well.Statistical Analysis
We used GraphPad Prism software (version 5 for Windows, GraphPad Soft-
ware Inc., La Jolla, CA) for statistical analysis. Bar graphs and data point
comparisons were analyzed using the student t test. Longitudinal curve
comparison was performed using two-way ANOVA. All p values presented
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